论文信息 - A randomized open‐label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection

A randomized open‐label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection

Polylactic acid (PLA, New‐Fill®; Medifill, London, UK and Dermic Labs, a division of Eventis, Strasbourg, France) injections into the deep dermis increase fibroblast numbers and collagen production. The substance is widely used in medical applications including cosmetic procedures.

[1] J W Eaton,et al. Inflammatory responses to biomaterials. , 1995, American journal of clinical pathology.

[2] S. Perren,et al. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). , 1993, Journal of biomedical materials research.

[3] A. Carr. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study , 2003, The Lancet.

[4] G. Chernoff,et al. Autologous Cultured Fibroblasts: A Protein Repair System , 2000, Annals of plastic surgery.

[5] L. Cooperman,et al. Injectable collagen: A six-year clinical investigation , 2005, Aesthetic Plastic Surgery.